Gufic Biosciences has made further investment of $50,000 in Selvax by way of subscription to 3,78,350 Ordinary shares at AUD 20 cents per share on April 28, 2026. The acquisition of equity shares in Selvax is a strategic arrangement for the development of immunotherapy solutions in oncology and is intended to enable the company to diversify into the healthcare and biotechnology sector and participate in the development of immunology-based treatments for large solid tumours. 

The investment aligns with the company’s long-term strategy of strategic diversification and value creation, providing access to proprietary technology, research capabilities and potential commercial opportunities in both human and veterinary oncology and is expected to generate sustainable long-term benefits for the company and its stakeholders once the therapy is medically commercialised. Total number of Ordinary shares held after post-acquisition is 16,85,350 shares. 

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.